However, patients carrying TNKS2 rs1340420 G/G and A/G genotypes were associated with a lower risk of developing NSCLC and adenocarcinoma (OR=0.14; 95% CI=0.02-1.15 and OR=0.11; 95% CI=0.03-0.91, respectively), whereas females patients homozygous for the TNKS2 rs1770474 T allele, a rare type, were associated with a higher risk of developing squamous-cell carcinoma (SCC) (OR=4.67; 95% CI=0.87-25.01).